ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 914,65
-0,88%
Dow Jones
38 225,66
0,85%
DAX
17 896,50
-0,14%
Brent Oil
83,795
0,20%
Bitcoin
59 584,53
0,78%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Sunshine Biopharma Inc (SBFM)

  7. Sunshine Biopharma Inc (SBFM) Actualités

SBFM Sunshine Biopharma Inc

0,838
-0,0222 (-2,58%)
03 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Sunshine Biopharma Inc SBFM NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,0222 -2,58% 0,838 01:59:33
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,8662 0,80 0,876381 0,8375 0,8602
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
06/3/202422:05EDGAR2Form 8-K - Current report
05/3/202422:37EDGAR2Form PRE 14C - Other preliminary information statements
05/3/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202422:03EDGAR2Form SC 13G - Statement of acquisition of beneficial..
21/2/202422:28EDGAR2Form SC 13G - Statement of acquisition of beneficial..
21/2/202414:24EDGAR2Form PRE 14C - Other preliminary information statements
16/2/202423:01EDGAR2Form 8-K - Current report
15/2/202417:39EDGAR2Form 8-K - Current report
14/2/202421:53EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/2/202417:18EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
13/2/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
12/2/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202415:04EDGAR2Form 8-K - Current report
09/2/202423:17EDGAR2Form S-1/A - General form for registration of securities..
01/2/202422:17EDGAR2Form S-1 - General form for registration of securities under..
30/1/202418:38EDGAR2Form 8-K - Current report
08/1/202414:10EDGAR2Form S-8 - Securities to be offered to employees in employee..
07/12/202322:59EDGAR2Form 8-K - Current report
04/12/202314:30GLOBESunshine Biopharma Moves Principal Office to New York City
13/11/202315:00EDGAR2Form 8-K - Current report
13/11/202314:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202317:18EDGAR2Form 8-K - Current report
20/10/202319:06EDGAR2Form 8-K - Current report
19/10/202318:10EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
18/10/202319:32EDGAR2Form DEF 14A - Other definitive proxy statements
13/10/202316:44EDGAR2Form 8-K - Current report
05/9/202322:20EDGAR2Form DEF 14A - Other definitive proxy statements
25/8/202321:16EDGAR2Form PRE 14A - Other preliminary proxy statements
11/8/202315:00EDGAR2Form 8-K - Current report
11/8/202314:30GLOBESunshine Biopharma Reports 2023 Second Quarter Results:..
10/8/202323:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
16/5/202315:58GLOBESunshine Biopharma Announces Closing of $5.0 Million Private..
12/5/202314:00GLOBESunshine Biopharma Announces Pricing of $5.0 Million Private..
11/5/202315:00GLOBESunshine Biopharma Reports 2023 First Quarter..

Dernières Valeurs Consultées

NASDAQ
SBFM
Sunshine Biopharma
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés